The New Standard for Infectious Disease Vaccines
The New Standard for Infectious Disease Vaccines
The Vaccine Platform
Vaxxirna’s ribozyme catalyzes the formation of circular RNA without the use of ligase enzymes: a molecular
architecture designed for stability and sustained immune activation.
Circular RNA designed
for durable protection
and real-world
deployment
Vaxxirna’s platform is designed to address key limitations of first-generation linear mRNA vaccine technologies, including short-lived antigen expression, tolerability challenges, and reliance on ultra-cold-chain logistics.
By using a circular RNA format, Vaxxirna is developing vaccines intended to support sustained antigen expression, robust immune activation, improved tolerability, and formulations suitable for distribution and use in low-resource settings.
The viRNA™ platform is built to support multiple vaccine modalities within a single, consistent technology framework. Rather than optimizing RNA for a single pathogen or application, the platform is designed to scale across infectious disease programs with shared infrastructure and accelerated iteration.
Vaxxirna is advancing multiple vaccine programs in parallel, powered by real-time data to accelerate decision-making and compress development timelines.
viRNA™ Vaccine Advantages
Immune and Antibody Response
Generates strong, sustained immunity and high antibody titers. Antigens are expressed over an extended period, supporting durable protection against target pathogens.
Rapid Adaptability
Easily redesigned for new or emerging pathogens, powered by AI-driven sequence optimization for faster development cycles and pandemic preparedness.
Thermostable Nanoparticles
Stable at room temperature, removing the cold-chain burden that limits vaccine access in lower-income and remote regions.
Microneedle Patch Delivery
Painless, injection-free self-administration improves compliance and opens access to populations with limited healthcare infrastructure.
Vaccine Applications
The viRNA™ platform is being developed to support a broad range of infectious disease applications, including:
Prophylactic vaccines for high-priority pathogens and emerging infectious threats
Therapeutic vaccines modulating host immune response in active or chronic
infection
Pandemic preparedness platforms enabling rapid response to novel
pathogens
Development Strategy
Vaxxirna’s development strategy is designed to achieve speed, rigor, and capital efficiency. Platform-level insights from lead programs inform and accelerate subsequent indications, reducing risk and supporting disciplined pipeline expansion.
The company’s lead infectious disease program is intended to provide early clinical validation of the viRNA™ platform, while subsequent vaccine programs represent expanding real-world impact and long-term value creation.